Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation and cyclin D1 over-expression. A biologically and clinically heterogeneous lymphoma, MCL, remains clinically challenging, with no proven curative therapy and no established standard of care. However, there have been considerable advances in the last several years in the treatment and understanding of MCL with the FDA approval of lenalidomide and ibrutinib, the development of other potentially active novel agents and the identification of recurrent mutations through new genomic sequencing approaches that may contribute to the biology of MCL and to therapeutic resistance. At the Lymphoma Research Foundation's 11th MCL Workshop, researchers gathered to discuss recent studies and current issues related to the biology of MCL, novel therapeutic targets and new treatment strategies. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.

Keywords::

• Lymphoma and Hodgkin's disease
• immunotherapy
• pharmacotherapeutics
• marrow and stem cell transplantation clinical results

Acknowledgments

This meeting, as well as some of the projects presented, was supported by grants from the Lymphoma Research Foundation Mantle Cell Lymphoma Initiative and the MCL Consortium. Each presenter whose work is included herein reviewed and approved the summary of that work. Meeting support was provided by the LRF and by Celgene Corporation and Millennium: The Takeda Oncology Company.

Potential conflict of interest

All co-authors are members of the LRF MCL Consortium Executive Committee; BK, LG, RG and ES are also members of LRF's Scientific Advisory Board. These proceedings were drafted with assistance from freelance writer Melinda B Tanzola, PhD and LRF Staff Member Whitney Steen. Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal